Tunable Rigid Spikes on Virus-Like Porous Silica Enable Mechanistically Controlled Nanovaccine Platforms
Cui Pang, Jiajia WangiD, Ahmed Montaser, Shuhao Ma, Henri LeinoneniD, Guoqing Hu, Vesa‐Pekka LehtoiD, Li Fan, Wujun XuiD
Abstract
Virus-like particles represent an emerging and promising vaccine platform. However, these particles are inherently mechanically soft and have limited control over particle surface architecture, thereby constraining their immunological control. Herein, we report the rational design of bioinspired virus-like porous silica (VLPSi) nanoparticles (NPs) with tunable and mechanically rigid spike architectures that function dually as antigen delivery carriers and immune adjuvants. Using ovalbumin (OVA) as a model antigen, we systematically elucidate the spiky structure-function relationship in antigen delivery and immune response. VLPSi NPs exhibit good biocompatibility, sustained antigen release, and markedly enhanced cellular uptake and endosomal escape compared with soft spike and spherical counterparts. Mechanistic investigations combining molecular dynamics simulations and proteomic analyses reveal that rigid spike architectures reduce the energetic barrier for cellular internalization and concurrently activate dual pathways involving endosomal Toll like receptors and calcium signaling. Consequently, VLPSi with long spikes elicit significantly enhanced humoral and cellular immune responses, outperforming the particles with shorter spikes, spherical shape as well as clinically used alum adjuvant. To demonstrate translational potential, bioinspired antibacterial vaccines were produced by loading Staphylococcus aureus surface protein rEsxB. The VLPSi-based vaccine elicited robust protective immunity to achieve complete (100%) survival following lethal challenge without detectable adverse effects, whereas traditional Alum-adjuvanted formulation conferred only minimal protection, with a survival rate of 10%. Collectively, this work establishes VLPSi with tunable spikes as a mechanistically controlled platform for next generation vaccines. Graphic Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=145 SRC="FIGDIR/small/720861v1_ufig1.gif" ALT="Figure 1"> View larger version (47K): org.highwire.dtl.DTLVardef@1f6c13eorg.highwire.dtl.DTLVardef@1090d07org.highwire.dtl.DTLVardef@1364926org.highwire.dtl.DTLVardef@fc68ab_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 40th percentile
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mechanism of biomimetic virus-like nanoparticles in triggering immune response elucidated by proteomics
Jiajia Wang, Ahmed B. Montaser, … Wujun Xu·Colloids and Surfaces B BiointerfacesPeer-reviewed·Dec 2, 2025
- A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.
Daniel P. Mayer, Mariah E. Nelson, … Jason S. Weinstein·Journal of Controlled ReleasePeer-reviewed·May 11, 2024
- pH-responsive nano-vaccines as antigen and adjuvant carrier that improve vaccine immunogenicity
J. Smith, D. Freeman·bioRxiv·Apr 24, 2019
- Self-Assembled Protein Vesicles as Vaccine Delivery Platform to Enhance Antigen-Specific Immune Responses
Yirui Li, Mariela R. Rodriguez-Otero, Julie A. Champion·BiomaterialsPeer-reviewed·Feb 29, 2024
- A rapidly adaptable biomaterial vaccine for SARS-CoV-2
F. Langellotto, B. T. Seiler, … D. J. Mooney·bioRxiv·Jul 7, 2020
- Improved humoral immunity and protection against influenza virus infection with a 3D porous biomaterial vaccine
H. Miwa, O. Q. Antao, … D. Di Carlo·bioRxiv·Dec 16, 2022